THE EFFECT OF AN IRON SUPPLEMENT ON SERUM ALUMINUM LEVEL AND DESFERRIOXAMINE MOBILIZATION TEST IN HEMODIALYSIS PATIENTS

• Published in: Renal failure Vol. 23; no. 6; pp. 789 - 795
• Main Authors: Huang, Jeng-Yi, Wu, Mai-Szu, Wu, Ching-Herng
• Format: Journal Article
• Language: English
• Published: Colchester Informa UK Ltd 01.01.2001; Taylor & Francis
• Subjects: Adult; Aged; Aged, 80 and over; Aluminum; Aluminum - blood; Anemia, Iron-Deficiency - blood; Anemia, Iron-Deficiency - drug therapy; Anemia, Iron-Deficiency - etiology; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Biological and medical sciences; Deferoxamine; Desferrioxamine; Emergency and intensive care: renal failure. Dialysis management; Female; Ferritins - blood; Humans; Intensive care medicine; Iron - administration & dosage; Iron - blood; Iron saturation; Male; Medical sciences; Middle Aged; Renal Dialysis - adverse effects; Uremia; Uremia - therapy; Human; Aluminum polymer; Hemodialysis; Iron deficiency anemia; Hemopathy; Iron; Deferoxamine; Extrarenal dialysis; Treatment; Overload; Serum; Supplementation; Sideropenia; Quantitative analysis

Background. The serum aluminum (Al) measurement with desferrioxamine (DFO) mobilization is a screening test for uremic patients with an Al overload. In these patients, body iron status is one of the factors affecting the serum Al level. This study is designed to elucidate the effects of iron supplem...